{"id":6853,"date":"2023-06-09T07:40:00","date_gmt":"2023-06-09T07:40:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/"},"modified":"2023-06-09T07:40:00","modified_gmt":"2023-06-09T07:40:00","slug":"nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/","title":{"rendered":"Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20"},"content":{"rendered":"
\n

Nanexa AB meddelar idag meddelar att rekrytering och dosering har slutf\u00f6rts i NEX-20 Fas 1-studien. Sedan december f\u00f6rra \u00e5ret har friska frivilliga administrerats singeldoser i tre p\u00e5 varandra f\u00f6ljande eskalerande dosgrupper. Data f\u00f6r farmakokinetisk profil, s\u00e4kerhet och tolerabilitet samlas nu in f\u00f6r den sista dosgruppen och resultat f\u00f6rv\u00e4ntas presenteras efter sommaren.<\/strong><\/p>\n<\/div>\n

\n

"Vi \u00e4r mycket glada \u00f6ver att ha slutf\u00f6rt rekryteringen enligt tidpplan och vi ser fram emot att utv\u00e4rdera studieresultaten f\u00f6r NEX-20", s\u00e4ger David Westberg, VD f\u00f6r Nanexa. "Jag \u00e4r mycket stolt \u00f6ver v\u00e5rt projektteam som \u00e4r dedikerat till att leverera den h\u00e4r studien enligt v\u00e5ra tidsatta m\u00e5l och att generera h\u00f6gkvalitativa data f\u00f6r att vi ska kunna ta n\u00e4sta steg i NEX-20- projektet. Vi vet fr\u00e5n diskussioner med v\u00e5r internationella advisory board att f\u00f6ljsamheten till den f\u00f6reskrivna behandlingen med lenalidomid kan vara suboptimal f\u00f6r vissa patienter, och eftersom fler och fler patienter globalt behandlas med lenalidomid under l\u00e5ng tid, ser vi tydligt att det finns ett otillfredsst\u00e4llt medicinskt behov d\u00e4r vi kan hj\u00e4lpa genom att tillhandah\u00e5lla en dep\u00e5formulering som NEX-20. \u201d<\/p>\n

NEX-20 \u00e4r en l\u00e5ngtidsverkande formulering av lenalidomid, baserad p\u00e5 Nanexas drug delivery-system PharmaShell\u00ae. Lenalidomid \u00e4r en immunmodulerande substans som verkar s\u00e5v\u00e4l p\u00e5 cancercellerna som p\u00e5 den omgivande mikromilj\u00f6n (1). Idag ges lenalidomid till patienter i form av en oral kapsel en g\u00e5ng om dagen under 21-28 dagar i str\u00e4ck i behandlingscykler om 28 dagar.<\/p>\n

1) A review of the history, properties, and use of the immunomodulatory compound lenalidomide Zeldis et al. Ann NY Acad Sci. 2011 Mar;1222:76-82<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar idag meddelar att rekrytering och dosering har slutf\u00f6rts i NEX-20 Fas 1-studien. Sedan december f\u00f6rra \u00e5ret har friska frivilliga administrerats singeldoser i tre p\u00e5 varandra f\u00f6ljande eskalerande dosgrupper. Data f\u00f6r farmakokinetisk profil, s\u00e4kerhet och tolerabilitet samlas nu in f\u00f6r den sista dosgruppen och resultat f\u00f6rv\u00e4ntas presenteras efter sommaren.<\/p>\n","protected":false},"template":"","class_list":["post-6853","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag meddelar att rekrytering och dosering har slutf\u00f6rts i NEX-20 Fas 1-studien. Sedan december f\u00f6rra \u00e5ret har friska frivilliga administrerats singeldoser i tre p\u00e5 varandra f\u00f6ljande eskalerande dosgrupper. Data f\u00f6r farmakokinetisk profil, s\u00e4kerhet och tolerabilitet samlas nu in f\u00f6r den sista dosgruppen och resultat f\u00f6rv\u00e4ntas presenteras efter sommaren.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\\\/\",\"name\":\"Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2023-06-09T07:40:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20 - Nanexa AB","og_description":"Nanexa AB meddelar idag meddelar att rekrytering och dosering har slutf\u00f6rts i NEX-20 Fas 1-studien. Sedan december f\u00f6rra \u00e5ret har friska frivilliga administrerats singeldoser i tre p\u00e5 varandra f\u00f6ljande eskalerande dosgrupper. Data f\u00f6r farmakokinetisk profil, s\u00e4kerhet och tolerabilitet samlas nu in f\u00f6r den sista dosgruppen och resultat f\u00f6rv\u00e4ntas presenteras efter sommaren.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/","name":"Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2023-06-09T07:40:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-slutfort-den-planerade-rekryteringen-till-fas-1-studien-av-nex-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa har slutf\u00f6rt den planerade rekryteringen till Fas 1-studien av NEX-20"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}